Carmex Cold Sore Treatment Claims Exceed Monograph Limit In NAD Review
Carma Labs’ Carmex Cold Sore Treatment claims did not mirror language in two OTC monographs for its active ingredients, the National Advertising Division says in a review of packaging and advertising claims challenged by GlaxoSmithKline's consumer business.
You may also be interested in...
Review was second in two years by the Council of Better Business Bureaus' National Advertising Division of a challenge to Reckitt Benckiser ad claims for its Mucinex cough/cold line made by Procter & Gamble, which markets competing products including Vicks NyQuil and DayQuil brands.
Kramer Laboratories' claims for Fungi-Nail athlete's foot product referred to FDA and FTC after it refuses to comply with NAD's recommendation to modify the name. The firm, which agreed to modify packaging and commercial claims, was warned by FDA about the brand in 2005.
SmithKline Beecham's Abreva, now hitting shelves in food, drug and mass outlets, is the first OTC indicated for shortening the healing time and duration of symptoms related to cold sores and fever blisters.